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Summary
The epidemiology of varicella is believed to differ between temperate and tropical countries. We 
conducted a varicella seroprevalence study among elementary and college students in the US-
territory of American Samoa before introduction of a routine varicella-vaccination program. Sera 
from 515 elementary and 208 college students were tested for the presence of varicella-zoster 
virus (VZV) IgG antibodies. VZV seroprevalence increased with age from 76.0% in the 4–6 year-
olds to 97.7% in those ≥23 years-old. Reported history of varicella disease for elementary students 
was significantly associated with VZV seropositivity. The positive and negative predictive values 
of varicella disease history were 93.4% and 36.4% in elementary students and 97.6% and 3.0% in 
college students. VZV seroprevalence in this Pacific island appears to be similar to that in 
temperate countries and suggests endemic VZV circulation.
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INTRODUCTION
Varicella is a highly infectious disease caused by the varicella zoster virus (VZV) [1]. 
Although varicella is usually self-limiting in children, infants less than one year of age, 
adults, and immunocompromised persons are at greater risk for severe complications that 
can result in death or require hospitalization [2]. Although VZV infections occur worldwide, 
the epidemiology has been reported to differ between countries with tropical climates 
compared to those with temperate climates [3]. In temperate climates, varicella is a nearly 
universal disease of preschool and school-aged children with peak incidence occurring 
during late winter and early spring [4]. Varicella seroprevalence studies from temperate 
countries, such as the United States [5] and western Europe [6], report seropositivity rates of 
>90% among persons >15 years old. However, in tropical countries, a greater proportion of 
adolescents and young adults have been found to be seronegative for antibodies to VZV [3]. 
As a result, these populations remain at risk for varicella at an older age, when it can result 
in higher rates of complications, hospitalizations, and deaths [1].
The varicella immunization program in the United States has resulted in a 90% reduction in 
varicella incidence in all age groups [7], >65% decline in varicella-related hospitalizations 
[8], and 96% decline in varicella-related deaths in persons <50 years [9]. American Samoa 
(AS), an unincorporated territory of the United States, plans to introduce varicella 
vaccination as part of their routine immunization program although the specific timeline is 
unknown; varicella vaccine is not available in the public or private sector in AS at this time. 
With limited varicella surveillance data from the Pacific Islands, there is little known about 
the epidemiology of varicella in this region. We conducted a VZV seroprevalence study in 
AS among elementary and college students to provide baseline data to monitor the impact of 
a future vaccination program on the epidemiology of varicella in AS.
METHODS
Study Location
American Samoa (AS) consists of six islands located between Hawaii and New Zealand in 
the South Pacific Ocean [10]. It lies at a latitude of 14°20’S and a longitude of 170°00'W. 
AS is a tropical island with an average temperature of 26.7 °C (80 °F), high humidity 
throughout the year, and average monthly rainfall of 9.91 in (251mm). In 2010, the 
population of AS was 55519 with an estimated annual birth cohort of 1260 children; 95% of 
the population resides on the main island of Tutuila [11].
Study Participants
The AS Department of Health in collaboration with AS Department of Education invited 
principals of all private and public elementary schools on the main island of Tutuila to 
participate in a seroprevalence study of vaccine-preventable diseases to assess immunity 
against hepatitis B, measles, mumps, rubella, and varicella among first-grade students. We 
also invited all students from the community college in AS, all of whom only attend college 
on the island, to participate in a study assessing varicella seroprevalence and measuring the 
anamnestic response to single dose of hepatitis B vaccination.
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This study was reviewed by the AS Department of Health Institutional Review Board and 
the CDC NCIRD Human Subjects Office. Written informed consent was obtained from 
participating college students and from parents of elementary students.
Study Questionnaire, Specimen Collection and Laboratory testing
A standard questionnaire, written in both English and Samoan, was distributed to parents/
guardians of first-grade students of participating elementary schools and participating 
college students to collect demographic information, and self-reported varicella disease and 
vaccination histories. Varicella disease history was based on parental/guardian report for 
elementary school students, while this information was based on self-report for college 
students. Information on varicella vaccination history was also retrieved from immunization 
cards.
Five to ten milliliters of venous blood were collected in April–May 2011 from study 
participants. The blood samples were centrifuged and the sera was stored at −20°C at the 
main hospital in AS. Sera were transported on dry ice to the CDC National VZV Laboratory 
in Atlanta, GA and tested for VZV-specific immunoglobulin G (IgG) antibodies by using 
CDC’s standard protocol. Specimens were tested by whole-cell enzyme-linked 
immunosorbent assay (ELISA); samples that yielded negative results were retested using the 
more sensitive IgG glycoprotein (gp) ELISA, as previously described [12, 13].
Analysis
Data were analyzed using SAS (Version 9.3; Cary, NC). We used Pearson’s χ2 or Fisher’s 
exact test to analyze categorical variables. A significant association was defined as one with 
a two-sided P-value of <.05. We calculated 95% exact binomial confidence intervals. The 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
of self-reported history of varicella in comparison with VZV IgG results were calculated for 
elementary and college students separately.
RESULTS
Among the 36 elementary schools in Tutuila Island, students in 27 (75%) schools agreed to 
participate in the study. Adequate samples for VZV testing were collected from 39% 
(515/1310) elementary and 12% (208/1787) college students. The median age of participants 
was 6 years (range, 4–9 years) for elementary school students and 20 years (range, 17–35 
years) for college students. There were 18 (3.5%) elementary students and 1 (0.5%) college 
student participant with 1-dose of varicella vaccination documented.
VZV seroprevalence increased from 76% in the 4–6 year-olds to 98% in those ≥23 years-
old. History of prior varicella disease for elementary school students was significantly 
associated with VZV seropositivity (Table 1).
A total of 651 study participants (89% (458/515) elementary school students and 93% 
(193/208) college students) provided information on varicella disease history (Table 2). The 
PPV and NPV of varicella disease history for VZV IgG positivity for elementary school 
students based on parental/guardian report was 93.4% (95% CI: 89.1%–96.3%) and 36.4% 
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(95% CI: 30.4%–42.8%) respectively. The PPV and NPV of VZV IgG positivity for college 
students based on self-report was 97.6% (95% CI: 93.3%–99.5%) and 3.0% (95% CI: 0.4%–
10.5%) respectively. For elementary school students, the sensitivity of reported disease 
history was 55.7% (95% CI: 50.3%–60.9%) and specificity was 86.5% (95% CI: 78.5%–
92.4%); for college students, sensitivity was 66.0% (95% CI: 58.7%–72.7%) and specificity 
was 40.0% (95% CI: 5.3%–85.3%).
DISCUSSION
This is the first published report describing VZV seroprevalence in AS. Rates of VZV 
seropositivity were high for all age groups tested and increased substantially with age, with 
>97% of ≥17 year-olds VZV seropositive. As in other studies of varicella seroprevalence 
conducted in populations prior to introduction of varicella vaccine, reported varicella disease 
history was highly predictive of VZV seropositivity for both elementary and college 
students in AS, whereas a negative history was a poor predictor of VZV seronegativity.
The high varicella seroprevalence rates we report for AS are similar to those found in recent 
studies from temperate countries [5, 6] and comparable to seroprevalence rates in the United 
States before the implementation of the 1-dose routine varicella vaccination program in 
1995, although U.S. seroprevalence was lower in children aged 4–10 years-old compared to 
this population [14]. The varicella sero-epidemiology in AS reported in this study is higher 
than that in serosurveys conducted in other tropical island populations [3, 15–18]. A 
serosurvey conducted among young adult military recruits found that 38% from the Pacific 
Island nations of the Federated States of Micronesia and the Republic of the Marshall 
Islands during 1988–1990 were VZV seronegative, as were 42% from Puerto Rico during 
1986–1987 [17, 18]. There are several possible explanations for differences in the 
seroepidemiology in AS compared to that previously reported for other islands and regions 
with similar climates. Daycare attendance by young children in AS has become quite 
common and high seroprevalence in AS could be facilitated by increased opportunities for 
transmission among young children attending daycares [4, 19]. Sera for some of the 
seroprevalence studies conducted in tropical climates were collected 20–30 years ago [16–
18] and may not be reflective of the VZV epidemiology today. Finally, results from our 
study may not be directly comparable to earlier studies that used less sensitive VZV 
serological assays [13].
Because our study included participants from a limited number of birth cohorts, we cannot 
fully describe the epidemiology of varicella in AS. The high rates of VZV seropositivity in 
AS that we found may be related to endemic VZV transmission or the result of periodic 
epidemics of varicella which could result in nearly all susceptibles in this island population 
becoming infected. Although varicella is not a reportable condition in AS, Department of 
Health staff report that varicella appears to circulate continuously in this small island 
population and that there have been no large outbreaks of varicella observed in recent years.
We found that parental recall of prior varicella disease history was not a reliable indicator 
for VZV seroprevalence in AS, with only 46% of parents recalling history among 
elementary school students, yet a VZV seroprevalence rate of almost 80%. The discrepancy 
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in parental report of varicella history and VZV seroprevalence that we found in our study 
may be due to off-island varicella vaccination history not captured by our study, survey 
question translation into the local language, lower parental recognition of varicella in AS, or 
asymptomatic disease. Additional studies to evaluate the validity of parental recall in this 
population with laboratory testing may help to identify susceptible populations who should 
be vaccinated and prevent un-needed vaccinations. However, we did find a high positive 
predictive value for reported history of varicella disease and VZV seropositivity for both 
elementary and college-aged students. These data suggest that report of prior varicella 
disease history in this population may be a reliable indicator of VZV seropositivity if a 
varicella vaccination program is implemented in American Samoa.
There were several limitations to this study. We used a convenience sampling methodology 
that was limited to selected age groups and information was not available for non-
participants. However, given the relatively small population of AS, we believe that the VZV 
seroepidemiology we report is likely to be broadly reflective of the age groups tested. 
Because American Samoans can travel to and work freely in the United States, it is possible 
that some VZV seropositive participants who reported no varicella disease history may have 
received doses of varicella vaccine while residing temporarily off-island that were not 
captured in AS immunization records. We were unable to collect information about place of 
birth from the college students and therefore it is possible that exposure to VZV for some 
students may have occurred outside of AS.
The findings of our study demonstrate that there is high VZV seroprevalence in AS, even 
among the young, suggesting that the epidemiology of varicella in this tropical island 
country may be similar to that seen in more temperate climates. Varicella complications, 
although rare, have the potential to be fatal. In addition, varicella can result in lost days of 
school and work for affected families and require substantial public health resources to 
control outbreaks and manage severe disease [20]. With a safe and highly effective vaccine 
available, introduction of a routine varicella vaccination program can significantly reduce 
varicella disease burden as well as costs, resources, and time allocated for managing 
varicella cases and outbreaks [8, 9, 20–22].
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Table 2
Comparison of reported varicella disease history and VZV seropositivity status by reporting source, AS, 2011.
VZV IgG Antibodies
Reporting
Source of
Disease History
Reported
Varicella
Disease
History
Positive
#(Row %, 95%
CI)
Negative
#(Row %)
Total
Elementary Positive 197 (93) 14 (7) 211
School Negative 157(64) 90 (36) 247
Studentsa Total 354 (77) 104 (23) 458
College Positive 124 (98) 3 (2) 127
Studentsb Negative 64 (97) 2 (3) 66
Total 188 (97) 5 (3) 193
aVaricella disease history for elementary school students was based on report by parents or guardians of students.
bVaricella disease history for college students was based on self-report.
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